This announcement is a separate document:
康弘药业：北京市通商（深圳）律师事务所关于成都康弘药业集团股份有限公司2023年股票增值权激励计划股票增值权授予事项的法律意见书
Kanghong Pharmaceutical: Legal Opinion of Beijing Commerce (Shenzhen) Law Firm on the granting of stock value-added rights in the 2023 Stock Value-added Incentive Plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.